NDC 76413-132 Hydrocortisone Acetate

NDC Product Code 76413-132

NDC 76413-132-12

Package Description: 12 PACKET in 1 BOX > 1 SUPPOSITORY in 1 PACKET

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

NDC Product Information

Hydrocortisone Acetate Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Description

Each suppository for rectal administration contains 25 mg hydrocortisone acetate USP in a hydrogenated cocoglyceride base. Hydrocortisone acetate is a corticosteroid.Chemically, hydrocortisone acetate is pregn-4-ene-3, 20 dione, 21- (acetyloxy)-11, 17-dihydroxy-, (11β)- with the following structural formula:

Clinical Pharmacology

In normal subjects, about 26 percent of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces.Topical steroids are primarily effective because of their anti-inflammatory, antipruritic and vasoconstrictive action.

Indications And Usage

For use in inflamed hemorrhoids, post irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.

Contraindications

Hydrocortisone acetate suppositories are contraindicated in those patients with a history of hypersensitivity to any of the components.

Precautions

Do not use unless adequate proctologic examination is made.If irritation develops, the product should be discontinued and appropriate therapy instituted.In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

Pregnancy Category C

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well-controlled studies in pregnant women.It is not known whether this drug is excreted in human milk.Until adequate studies in pregnant or lactating women have been conducted, this drug should be used during pregnancy or by nursing mothers only when clearly needed and when the potential benefits outweigh the potential risks.

Adverse Reactions

  • The following local adverse reactions have been reported with corticosteroid suppositories:1.Burning2.Itching3.Irritation4.Dryness5.Folliculitis6.Hypopigmentation7.Allergic Contact Dermatitis8.Secondary Infection

Drug Abuse And Dependence

Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

Overdosage

If signs and symptoms of systemic overdosage occur, discontinue use.

Usual Dosage:

One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.

How Supplied

Hydrocortisone acetate suppositories are easy to open, color coded and available in cartons of:12'sNDC 76413-132-12

Storage And Handling

Store at controlled room temperature 15° to 30°C (59° to 86°F). Protect from freezing.

Other

Manufactured ByPerrigo®Minneapolis, MN 55427(01-12)

* Please review the disclaimer below.